Document is current
Any future updates will be listed below
-
Authors
Sheriff, Samran https://orcid.org/0009-0009-0813-3899
Saba, Maree https://orcid.org/0000-0002-1698-9891
Patel, Romika https://orcid.org/0009-0000-6523-8798
Fisher, Georgia https://orcid.org/0000-0002-7252-7800
Schroeder, Tanja https://orcid.org/0000-0002-1733-6542
Arnolda, Gaston https://orcid.org/0000-0003-4948-7633
Luo, Dan https://orcid.org/0000-0001-5291-8428
Warburton, Lydia https://orcid.org/0000-0001-9417-1596
Gray, Elin https://orcid.org/0000-0002-8613-3570
Long, Georgina https://orcid.org/0000-0001-8894-3545
Braithwaite, Jeffrey https://orcid.org/0000-0003-0296-4957
Rizos, Helen https://orcid.org/0000-0002-2094-9198
Ellis, Louise Ann https://orcid.org/0000-0001-6902-4578
-
Funding
Funding for this research was provided by:
Department of Health and Aged Care, Australian Government (GA176020)
- License Information
-
More Information
Article History
Received: 21 October 2024
Accepted: 6 February 2025
First Online: 12 February 2025
Declarations
:
: Not applicable as this study is a scoping review.
: Not applicable.
: GVL is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc, BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Evaxion Biotech A/S,GI Innovation Inc, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., IOBiotech, Immunocore Ireland Limited, Innovent Biologics USA Inc, Iovance Biotherapeutics Inc, Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec Medical Australia, PHMR Limited, Pierre Fabre, Regeneron Pharmaceuticals, Scancell Limited, SkylineDX B.V. “LW has received honoraria for Advisory Boards from Bristol Myers Squibb, AstraZeneca, Roche, Novartis, Pierre Fabre and Merck Sharp & Dohme and travel support from Merck Sharp & Dohme, AstraZeneca, and Bristol Myers Squibb”All other authors declare no conflict of interest.
